# PRODUCT INFORMATION

## SU6656

*Item No. 13338*

| | |
|---|---|
| **CAS Registry No.:** | 330161-87-0 |
| **Formal Name:** | 2,3-dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl) methylene]-1H-indole-5-sulfonamide |
| **MF:** | $C_{19}H_{21}N_3O_3S$ |
| **FW:** | 371.5 |
| **Purity:** | ≥95% |
| **UV/Vis.:** | $\lambda_{max}$: 232, 300, 445 nm |
| **Supplied as:** | A crystalline solid |
| **Storage:** | -20°C |
| **Stability:** | ≥4 years |



*Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.*

### Laboratory Procedures

SU6656 is supplied as a crystalline solid. A stock solution may be made by dissolving the SU6656 in the solvent of choice, which should be purged with an inert gas. SU6656 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of SU6656 in these solvents is approximately 20 mg/ml.

### Description

The Src family of proto-oncogenic kinases include nine mammalian non-receptor tyrosine kinases that are involved in intracellular signaling and are often relevant to carcinogenesis. SU6656 is a selective inhibitor of Src kinases, Including Src, Yes, Lyn, and Fyn ($IC_{50}$ = 280, 20, 130, 170 nM, respectively).[1] It weakly inhibits some other kinases when used at >10 µM.[1,2] SU6656 has been used to study the role of Src kinases in cell growth and development in diverse processes, including nervous system development, fibrosis, and cancer.[3-5]

### References


1. Blake, R.A., Broome, M.A., Liu, X., *et al.* SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. *Mol. Cell. Biol.* **20(23)**, 9018-9027 (2000).
2. Bain, J., McLauchlan, H., Elliot, M., *et al.* The specificities of protein kinase inhibitors: An update. *Biochem. J.* **371(Pt. 1)**, 199-204 (2003).
3. Jin, W., Yun, C., Jeong, J., *et al.* c-Src is required for tropomyosin receptor kinase C (TrkC)-induced activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. *J. Biol. Chem.* **283(3)**, 1391-1400 (2008).
4. Distler, J.H.W. and Distler, O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. *Rheumatology* **47(Suppl 5)**, 10-11 (2008).
5. Fossey, S.L., Liao, A.T., McCleese, J.K., *et al.* Characterization of STAT3 activation and expression in canine and human osteosarcoma. *BMC Cancer* **9:81**, (2009).





**CAYMAN CHEMICAL**
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
**PHONE:** [800] 364-9897
[734] 971-3335
**FAX:** [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM